Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865694 | 0.91 | — | — | |
| SCHEMBL25826798 | 0.88 | ABCB1 (0.34) | ABCB1NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL24140963 | 0.88 | ABCB1 (0.34) | ABCB1NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL14023067 | 0.88 | ABCB1 (0.37) | ABCB1NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL14023845 | 0.88 | ABCB1 (0.37) | ABCB1NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL15478873 | 0.88 | ABCB1 (0.37) | ABCB1NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL15381958 | 0.84 | ABCB1 (0.38) | ABCB1NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL17728769 | 0.82 | ABCB1 (0.31) | ABCB1 | |
| SCHEMBL30360070 | 0.82 | ABCB1 (0.35) | ABCB1 | |
| SCHEMBL24140468 | 0.82 | ABCB1 (0.35) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499152-B1 | TUBULIN INHIBITORS | TUBE PHARMACEUTICALS GMBH (AT) | 2016-06-29 | — | — | EP | disclosed |
| EP-2499153-B1 | Tubulin inhibitors | TUBE PHARMACEUTICALS GMBH (AT) | 2016-03-23 | — | — | EP | disclosed |
| US-9163060-B2 | Tubulin inhibitors | R&D BIOPHARMACEUTICALS GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-9163060-B2 | Tubulin inhibitors | R&D BIOPHARMACEUTICALS GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-8772244-B2 | Tubulin inhibitors | R&D BIOPHARMACEUTICALS GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-8772244-B2 | Tubulin inhibitors | R&D BIOPHARMACEUTICALS GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20120252739-A1 | Tubulin Inhibitors | R&D BIOPHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252738-A1 | Tubulin Inhibitors | R & D BIOPHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252739-A1 | Tubulin Inhibitors | R&D BIOPHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252738-A1 | Tubulin Inhibitors | R & D BIOPHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252738-A1 | Tubulin Inhibitors | TUBB1, TUBB, TUBA1C | ABCB1 344/4885NPC1 644/4885MAPT 30/4885 |
| US-20120252739-A1 | Tubulin Inhibitors | TUBB1, TUBB, TUBA1C | ABCB1 344/4885NPC1 644/4885MAPT 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.